Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Plby Group Inc (PLBY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Plby Group Inc — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.86B), while Plby Group Inc trades at $0.97 (market cap $122.20M). The key difference: Dyne Therapeutics Inc. Common Stock is far larger — about 23.4× Plby Group Inc's market cap, and Plby Group Inc is more actively traded (540,321 versus 3,341,579). Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Plby Group Inc for 24 Days on average.
| DYN | PLBY | |
|---|---|---|
Market Cap | $2.86B | $122.20M |
Volume | 3,341,579 | 540,321 |
Sector | Health | Consumer Cyclical |
52-Week High | $26.78 | $2.71 |
52-Week Low | $14.60 | $0.98 |
Typical Hold Time | 0 Days | 24 Days |
Enterprise Value | $2.18B | $267.79M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
PLBY trades at $0.99, down 0.32% with a bearish technical signal. The company shows improving fundamentals with revenue stabilizing around $121M in 2025 and narrowing losses from -$278M in 2022 to -$13M. Recent Q2 2026 earnings beat expectations with positive operating cash flow. Analyst sentiment remains strong with 75% buy ratings, while technical indicators show oversold conditions with RSI at neutral levels.
The outlook suggests cautious optimism as PLBY demonstrates operational improvement and debt reduction, though negative shareholder equity and high P/E ratio of 51 present valuation concerns. Key risks include persistent negative equity and competitive pressures in the consumer discretionary space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Plby Group Inc
PLBY Group Inc is a pleasure and leisure company. The company's segment includes Licensing, Direct-to-Consumer, and Digital Subscriptions and Content. It generates maximum revenue from the Direct-to-Consumer segment. Direct-to-Consumer operations include consumer products sold through third-party retailers or online direct-to-customer. Geographically, it derives a majority of revenue from the United States.
Read more on PLBY →
